Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
34 participants
INTERVENTIONAL
2008-09-30
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism
NCT02034435
Aldosterone and Vascular Disease in Diabetes Mellitus
NCT00214825
Prospective Phenotyping of Autonomous Aldosterone Secretion
NCT03484130
The Role of Aldosterone in Circulatory Disorders Within Type 2 Diabetes
NCT03017703
Aldosterone in Diabetic Nephropathy
NCT00870402
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HS-V/A; LS-V/A
High Sodium diet- Vehicle infusion then Aldosterone infusion Low Sodium diet- Vehicle infusion then Aldosterone infusion
Aldosterone infusion (A)
Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)
Vehicle Infusion (V)
Vehicle infusion for 12.5 hours
High Sodium Diet (HS)
160 mmol/d sodium diet for 7 days
Low Sodium Diet (LS)
20 mmol/d sodium diet for 9 days
HS-A/V; LS-A/V
High Sodium diet- Aldosterone infusion then Vehicle infusion Low Sodium diet- Aldosterone infusion then Vehicle infusion
Aldosterone infusion (A)
Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)
Vehicle Infusion (V)
Vehicle infusion for 12.5 hours
High Sodium Diet (HS)
160 mmol/d sodium diet for 7 days
Low Sodium Diet (LS)
20 mmol/d sodium diet for 9 days
LS-V/A; HS-V/A
Low Sodium diet- Vehicle infusion then Aldosterone infusion High Sodium diet- Vehicle infusion then Aldosterone infusion
Aldosterone infusion (A)
Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)
Vehicle Infusion (V)
Vehicle infusion for 12.5 hours
High Sodium Diet (HS)
160 mmol/d sodium diet for 7 days
Low Sodium Diet (LS)
20 mmol/d sodium diet for 9 days
LS-A/V; HS-A/V
Low Sodium diet- Aldosterone infusion then Vehicle infusion High Sodium diet- Aldosterone infusion then Vehicle infusion
Aldosterone infusion (A)
Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)
Vehicle Infusion (V)
Vehicle infusion for 12.5 hours
High Sodium Diet (HS)
160 mmol/d sodium diet for 7 days
Low Sodium Diet (LS)
20 mmol/d sodium diet for 9 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aldosterone infusion (A)
Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)
Vehicle Infusion (V)
Vehicle infusion for 12.5 hours
High Sodium Diet (HS)
160 mmol/d sodium diet for 7 days
Low Sodium Diet (LS)
20 mmol/d sodium diet for 9 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. For female subjects, the following conditions must be met:
a postmenopausal status for at least 1 year, or b status-post surgical sterilization, or c if of childbearing potential, utilization of adequate birth control and willingness to undergo urine beta-hcg testing prior to drug treatment and on every study day
3. Metabolic Syndrome as defined by the presence of \> 3 of the following:
a Systolic Blood Pressure \> 130 mm Hg OR Diastolic Blood Pressure \> 85 mm Hg. b Glucose Intolerance (Fasting Plasma Glucose \> 100 mg/dL) c Increased triglyceride level \> 150mg/dL (1.7mmol/L) d Decreased levels of HDL cholesterol For males, less than 40 mg/dL For females, less than 50 mg/dL e Waist circumference For males, greater than 40 inches (102 cm) For females, greater than 35 inches (89 cm).
Exclusion Criteria
2. Prior allergies to medications used in the study protocol (e.g. L-arginine, potassium chloride).
3. Screening plasma potassium \<3.5 mmol/L or use of chronic potassium supplements for the treatment of hypokalemia
4. Use of hormone replacement therapy
5. If on statin therapy for hypercholesterolemia, a change in dose within the past 6 months.
6. Breast-feeding
7. Cardiovascular disease such as prior myocardial infarction, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis or hypertrophic cardiomyopathy
8. Treatment with anticoagulants
9. History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or transient ischemic attack
10. History or presence of immunological or hematological disorders
11. Diagnosis of asthma requiring use of inhaled beta agonist \>1 time per week
12. Clinically significant gastrointestinal impairment that could interfere with drug absorption
13. Impaired hepatic function \[aspartate amino transaminase (AST) and/or alanine amino transaminase (ALT) \>2.0 x upper limit of normal range\]
14. Impaired renal function \[estimated glomerular filtration rate (eGFR) of \<60ml/min\] as determined by the four-variable Modification of Diet in Renal Disease (MDRD) equation, where serum creatinine (Scr) is expressed in mg/dl and age in years:
15. eGFR \<60 ml/min
16. Hematocrit \<35%
17. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult, such as arthritis treated with non-steroidal antiinflammatory drugs
18. Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)
19. Treatment with lithium salts
20. History of alcohol or drug abuse
21. Treatment with any investigational drug in the 1 month preceding the study
22. Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study
23. Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Vanderbilt University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
James Matt Luther
Assistant Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James M Luther, MD
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ramirez CE, Shuey MM, Milne GL, Gilbert K, Hui N, Yu C, Luther JM, Brown NJ. Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans. Prostaglandins Other Lipid Mediat. 2014 Oct;113-115:38-44. doi: 10.1016/j.prostaglandins.2014.08.001. Epub 2014 Aug 28.
Luther JM, Byrne LM, Yu C, Wang TJ, Brown NJ. Dietary sodium restriction decreases insulin secretion without affecting insulin sensitivity in humans. J Clin Endocrinol Metab. 2014 Oct;99(10):E1895-902. doi: 10.1210/jc.2014-2122. Epub 2014 Jul 16.
Brown JM, Williams JS, Luther JM, Garg R, Garza AE, Pojoga LH, Ruan DT, Williams GH, Adler GK, Vaidya A. Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone. Hypertension. 2014 Feb;63(2):273-80. doi: 10.1161/HYPERTENSIONAHA.113.01910. Epub 2013 Nov 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
080248
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.